Diagnosis and treatment of chronic constipation: a European persp

Diagnosis and treatment of chronic constipation: a European perspective. Neurogastroenterol Motil. 2011;23(8):697–710.PubMedCrossRef 8. Pare P, Ferrazzi S, Thompson WG, et al. An epidemiological Selleck A-1210477 survey of constipation in Canada: definitions, rates, demographics, and predictors of health care seeking. Am J Gastroenterol. 2001;96(11):3130–7.PubMedCrossRef 9. Higgins PD, Johanson JF. Epidemiology of constipation in North America:

a systematic review. Am J Gastroenterol. 2004;99(4):750–9.PubMedCrossRef 10. Choung RS, Locke GR 3rd, Schleck CD, et al. Cumulative incidence Captisol manufacturer of chronic constipation: a population-based study 1988–2003. Aliment Pharmacol Ther. 2007;26(11–12):1521–8.PubMedCrossRef 11. Barditch-Crovo P, Trapnell CB, Ette E, et al. The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics

of a combination oral contraceptive. Clin Pharmacol Ther. AZD4547 molecular weight 1999;65(4):428–38.PubMedCrossRef 12. Bolt HM. Interactions between clinically used drugs and oral contraceptives. Environ Health Perspect. 1994;102(Suppl 9):35–8.PubMedCrossRef 13. European Medicines Agency. ICH harmonised tripartite guidelines for good clinical practice, 1996. http://​www.​emea.​europa.​eu/​pdfs/​human/​ich/​013595en.​pdf. Accessed 11 June 2012. 14. World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. http://​www.​wma.​net/​en/​30publications/​10policies/​b3/​. Accessed 12 August 2009. 15. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM). Guidance for industry: bioanalytical method validation, 2001. http://​www.​fda.​gov/​downloads/​Drugs/​GuidanceComplian​ceRegulatoryInfo​rmation/​Guidances/​ucm070107.​pdf. Accessed 14 December 2011. 16. Organisation for Economic Co-operation and Development. OECD principles of good laboratory practice (GLP). http://​www.​oecd.​org/​document/​63/​0,3746,en_​2649_​34377_​2346175_​1_​1_​1_​1,00.​html. Accessed 13 April 2012. 17. Hanker JP. Gastrointestinal disease and oral contraception.

Am J Obstet Gynecol. 1990;163(6 Pt 2):2204–7.PubMedCrossRef 18. Camilleri M, Van Outryve MJ, Beyens Liothyronine Sodium G, et al. Clinical trial: the efficacy of open-label prucalopride treatment in patients with chronic constipation: follow-up of patients from the pivotal studies. Aliment Pharmacol Ther. 2010;32(9):1113–23.PubMedCrossRef 19. Quigley EM, Tack J, Kerstens R, et al. The efficacy and safety of oral prucalopride in female patients with chronic constipation who had failed laxative therapy (EMA-authorised population) is similar to that of the ITT population in the initial pivotal trials: pooled data analysis. Gastroenterology. 2012;142(Suppl I):S820–1. 20. De Maeyer JH, Aerssens J, Verhasselt P, et al. Alternative splicing and exon duplication generates 10 unique porcine 5-HT 4 receptor splice variants including a functional homofusion variant.

Comments are closed.